Eruptive disseminated porokeratosis

Authors

  • María Belén Godoy President Dr. Nicolás Avellaneda Clinical Hospital, Tucumán, Argentina
  • Adriana Beatriz Liatto de Nogalo President Dr. Nicolás Avellaneda Clinical Hospital, Tucumán, Argentina
  • Tatiana Giselle Nogalo President Dr. Nicolás Avellaneda Clinical Hospital, Tucumán, Argentina
  • Silvia Graciela Molina President Dr. Nicolás Avellaneda Clinical Hospital, Tucumán, Argentina
  • Viviana Audi President Dr. Nicolás Avellaneda Clinical Hospital, Tucumán, Argentina

DOI:

https://doi.org/10.47196/da.v30i3.2672

Keywords:

porokeratosis, cornoid lamella

Abstract

Porokeratosis is a heterogeneous and rare group of acquired or inherited dermatoses of unknown etiology, characterized by a keratinization disorder secondary to an abnormal clonal expansion of keratinocytes. Eruptive disseminated porokeratosis (EDP) is an atypical variant with abrupt onset with more than 100 lesions involving multiple regions. It is subdivided into paraneoplastic, inflammatory, idiopathic and associated with immunosuppression. The case of a 28-year-old woman who consulted is presented. due to pruritic erythematous annular plaques with atrophic center and hyperkeratotic border of generalized distribution, with compatible dermoscopy and histopathology and partial response to topical treatment.

Author Biographies

María Belén Godoy, President Dr. Nicolás Avellaneda Clinical Hospital, Tucumán, Argentina

Resident Physician in Dermatology

Adriana Beatriz Liatto de Nogalo, President Dr. Nicolás Avellaneda Clinical Hospital, Tucumán, Argentina

Staff Physician, Dermatology Service, Deputy Director of the Dermatology Residency, Associate Professor of Dermatology (UNT)

Tatiana Giselle Nogalo, President Dr. Nicolás Avellaneda Clinical Hospital, Tucumán, Argentina

Dermatologist

Silvia Graciela Molina, President Dr. Nicolás Avellaneda Clinical Hospital, Tucumán, Argentina

Head of the Dermatology Service, Director of the Dermatology Residency

Viviana Audi, President Dr. Nicolás Avellaneda Clinical Hospital, Tucumán, Argentina

Head of the Pathological Anatomy Service

References

I. Gimeno Castillo J, De la Torre Gomar FJ. FR- Formulación tópica de estatinas y colesterol como tratamiento de poroqueratosis. Actas Dermosifiliogr. 2023;114:533-535.

II. Bonilla JD, Alzate B K, Motta A. Pápulas con bordes hiperqueratósicos en áreas fotoexpuestas. ¿Qué aporta la dermatoscopia? Rev Asoc Colomb Dermatol Cir Dermatol. 2021;29:229-232.

III. Yalcin B, Uysal PI, Kadan E, Bozdoğan Ö. Eruptive disseminated porokeratosis in a patient with type 2 diabetes mellitus. Am J Dermatopathol. 2016;38:125-127.

IV. Mangas C, Espeli V, Blum R. Un caso de poroqueratosis diseminada eruptiva en un paciente oncológico tratado con trastuzumab y exemestano: ¿fenómeno asociado al cáncer o inducido por fármacos? Actas Dermosifiliogr. 2018;109:559-560.

V. Shoimer I, Robertson LH, Storwick G, Haber RM. Eruptive disseminated porokeratosis: a new classification system. J Am Acad Dermatol. 2014;1:398-400.

VI. Pedrozo L, Rodríguez Saa S, Cohen-Sabban EN, Cabo H. Dermatoscopia de la poroqueratosis actínica superficial diseminada. Dermatol Argent. 2015;21:76-77.

VII. Valiente-Rebull C, Rodríguez L, Martínez-Braga G, Di Martino-Ortiz B, et ál. Poroqueratosis. Informe de tres casos. Our Dermatol Online. 2014;5:163-168.

VIII. Montes-Torres A, Camarero-Mulas C, De Argila D, Gordillo C, et ál. Poroqueratosis pruriginosa diseminada inflamatoria. Buena respuesta a ciclosporina. Actas Dermosifiliogr. 2016;107:261-262.

IX. Cazorla MB, Müller G, Yarza M, Navacchia D, et ál. Poroqueratosis de Mibelli en la edad pediátrica. Dermatol Argent. 2020;26:32-34.

X. Vargas-Mora P, Morgado-Carrasco D, Fustà-Novell X. Poroqueratosis. Revisión de su etiopatogenia, manifestaciones clínicas, diagnóstico y tratamiento. Actas Dermosifiliogr. 2020;111:545-560.

Published

2024-10-21

Issue

Section

Clinical Cases